BTK occupancy. In (A) PBMCs and (B) nodal tissue. Data for individual patients at each time point are shown. Patient numbers and the percentage of patients with >95% BTK occupancy are noted. Triangles indicate percentages of BTK occupancy in PBMCs of patients predose, at 4 and 24 hours after zanubrutinib treatment on day 1 of week 1 (W1D1), predose on day 3 of week 1 (W1D3), and day 1 of week 2 (W2D1). BTK occupancy in lymph node biopsy specimens was assessed at baseline and predose on W1D3 and calculated as 1 − ([free BTK on day 3 predose] × [total BTK at screening])/([free BTK at screening] × [total BTK on day 3 predose]). Median values are shown as lines through the individual triangles. DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MZL, marginal zone lymphoma.